v3.25.2
Supplemental Financial Information
 6 Months Ended
Jun. 30, 2025
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Supplemental Financial Information
Note 11. Supplemental Financial Information
The following table presents the components of inventories (in thousands):
June 30, 2025December 31, 2024
Raw materials$77,047 $71,949 
Work-in-process16,333 12,322 
Finished goods71,970 63,295 
 $165,350 $147,566 
As of June 30, 2025 and December 31, 2024, inventories included adjustments totaling $21.8 million and $16.4 million, respectively, to record balances at the lower of cost or net realizable value.
The following table presents the components of accrued liabilities and other (in thousands):
June 30, 2025December 31, 2024
Italian MedTech payback measure$19,690 $15,981 
Legal and professional costs18,972 17,379 
Contract liabilities11,176 10,848 
Operating lease liabilities9,380 9,040 
Interest payable5,245 9,479 
Provisions for agents, returns, and other4,869 6,744 
Royalty accrual4,771 4,466 
Research and development costs1,711 6,167 
Current derivative liabilities1,369 2,915 
Restructuring liabilities— 2,003 
Other accrued expenses26,057 33,463 
$103,240 $118,485 
As of June 30, 2025 and December 31, 2024, contract liabilities totaling $15.8 million and $14.7 million, respectively, were included in accrued liabilities and other long-term liabilities on the condensed consolidated balance sheets.
The following table presents the items included in foreign exchange and other income/(expense) on the condensed consolidated statements of income (loss) (in thousands):
Three Months Ended June 30,Six Months Ended June 30,
2025202420252024
Embedded derivative fair value adjustment (2025 Notes) (1)
$(489)$615 $1,552 $(1,363)
Embedded derivative fair value adjustment (2029 Notes) (1)
(10,867)(1,104)3,726 (7,935)
Capped call fair value adjustment (2025 Notes) (1)
498 (571)(1,321)(8,533)
Capped call fair value adjustment (2029 Notes) (1)
4,468 (1,493)(2,077)477 
Investment revaluation - Ceribell, Inc. (2)
(1,008)— (3,622)— 
Impairment of investment in ShiraTronics, Inc. (3)
— (5,750)— (5,750)
Interest income4,183 7,337 10,626 14,358 
FX fluctuations(1,240)(2,183)(1,850)(3,105)
Other200 104 127 (265)
$(4,255)$(3,045)$7,161 $(12,116)
(1)Refer to “Note 3. Fair Value Measurements.”
(2)During the second quarter of 2025, LivaNova liquidated its investment in Ceribell, Inc., consisting of 391,952 common shares, in a series of transactions with an average sales price of $16.69 per common share, resulting in net proceeds of $6.5 million from an initial investment in 2018 of $3.0 million.
(3)Impairment of equity investment related to LivaNova’s preferred share ownership converting into common stock of ShiraTronics, Inc. during the second quarter of 2024.
The following table presents a reconciliation of cash, cash equivalents, and restricted cash reported on the condensed consolidated balance sheets that sum to the total of the amounts shown on the condensed consolidated statements of cash flows (in thousands):
June 30, 2025December 31, 2024
Cash and cash equivalents$593,638 $428,858 
Restricted cash (1)
— 294,698 
$593,638 $723,556 
(1)On March 18, 2022, LivaNova PLC, acting through its Italian branch, entered into an Indemnity Letter and an Account Pledge Agreement with Barclays, further to which Barclays issued the SNIA Litigation Guarantee. As security for the SNIA Litigation
Guarantee, LivaNova was required to grant cash collateral to Barclays in USD in an amount equal to the USD equivalent of 105% of the amount of the SNIA Litigation Guarantee calibrated on a biweekly basis, which is presented as restricted cash on the condensed consolidated balance sheet. On March 31, 2025, as a result of the decision by the Italian Supreme Court, the SNIA Litigation Guarantee was terminated, and the restriction on the cash deposit held as collateral was released. For additional information, refer to “Note 5. Commitments and Contingencies.”